Fig. 1 · Structure

Documents & Downloads

Eribulin Mesylate

Cat. No. A12804 CAS 441045-17-6
Eribulin mesylate is the mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity.

In Stock

Publications for Eribulin Mesylate

3 publications citing this product

  1. Seungyeon Ryu, .et al. , Breast Cancer Res, 2025, Jun 23;27(1):113 PMID: 40551232
  2. Tomohiro Nabekura, .et al. , Biochem Biophys Rep, 2020, Mar; 21: 100727 PMID: 31993509
  3. Snyder C, .et al. , Toxicol In Vitro, 2018, Aug;50:109-123 PMID: 29427706

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Eribulin mesylate targets microtubules. Radiolabeled eribulin bound assembled microtubules at a low fitted maximum occupancy, supporting an end-binding interpretation. At 100 nM, it did not significantly alter minus-end dynamic-instability parameters. These findings support the authors' plus-end-directed mechanism, while the binding assay alone does not directly locate individual binding sites. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Eribulin Mesylate Research Summary

This section summarizes 4 in vitro studies and 2 in vivo studies of Eribulin Mesylate from 4 published references. In vitro models include steady-state, MAP-rich bovine brain microtubules; human intestinal epithelial LS174T cells.

Eribulin Mesylate In Vitro Studies

In human LS174T cells, 2 μM eribulin mesylate for 48 h increased MDR1 mRNA and P-glycoprotein protein expression relative to ethanol vehicle. A separate 0.5 μM, 96 h exposure reduced subsequent accumulation of two fluorescent transporter substrates after washout. These cell-model findings suggest a potential efflux-related limitation; they do not establish clinical drug resistance or a pharmacokinetic interaction. [2]

Radioligand binding to preassembled microtubules

Biochemical assay · Steady-state, MAP-rich bovine brain microtubules (3 mg/mL tubulin preparation) [1]

Saturable binding of radiolabeled eribulin to a small number of sites per microtubule supports an end-binding interpretation. The fitted maximum is an extrapolation, not a directly counted occupancy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Binding to assembled microtubulesKd 3.5 ± 0.6 μM (mean ± SEM; four experiments)[1]
Extrapolated maximum occupancy per microtubuleYmax 14.7 ± 1.3 eribulin molecules/microtubule (mean ± SEM; four experiments)[1]

Literature-Reported Treatment Conditions

Treatment concentration
[3H]eribulin 0.1–10 μM
Exposure duration
Approximately 1–2 min drug incubation before centrifugation
Method
Radioligand co-sedimentation; protein/radioactivity measurement and electron-microscopy length correction; nonlinear regression
Reported limits
Drug solvent not specified in relevant methods. Stabilizing cushion contains glycerol/DMSO; it is not evidence of the dosing vehicle.
Methods and source locations

Compound reported in the paper: Eribulin mesylate; Compound label in the paper: E7389 / eribulin

Applies to the material and assay reported in this paper; no salt conversion, stereoisomer substitution or validation of a current Adooq lot.

Materials and Methods: Eribulin; Eribulin Binding to Microtubules and Microtubule Length Determination; Results: Eribulin Binds to Microtubule Ends; Figure 3A–B and caption

Binding to assembled microtubules: Nonlinear regression of individual binding experiments; mean and standard error across experiments — Materials and Methods: Eribulin; Eribulin Binding to Microtubules and Microtubule Length Determination; Results: Eribulin Binds to Microtubule Ends; Figure 3A–B and caption

Extrapolated maximum occupancy per microtubule: Pellet radiolabel/protein and measured microtubule length; correction for length changes at 5 and 10 μM — Materials and Methods: Eribulin; Eribulin Binding to Microtubules and Microtubule Length Determination; Results: Eribulin Binds to Microtubule Ends; Figure 3A–B and caption

Minus-end dynamics at 100 nM eribulin

Biochemical assay · Microtubules assembled from 18 μM phosphocellulose-purified bovine tubulin using axonemal seeds [1]

At 100 nM eribulin, the authors found no significant changes in minus-end dynamic-instability parameters. This limits a general claim that eribulin suppresses dynamics at both microtubule ends.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Minus-end growth rate, control versus 100 nM eribulinGrowth rate Control: 0.6 ± 0.1 μm/min; eribulin: 0.6 ± 0.02 μm/min; ns (± SEM)[1]
Minus-end growing length, control versus 100 nM eribulinGrowing length Control: 0.9 ± 0.1 μm; eribulin: 0.8 ± 0.1 μm; ns (± SEM)[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM eribulin
Exposure duration
30 min assembly to steady state at 35 °C; individual microtubules recorded for 10 min
Method
Video-enhanced differential interference contrast microscopy; growth/shortening event analysis
Reported limits
Drug solvent and number of independent preparations not specified in this assay description. The stated 45–50 events per condition are event counts, not independent biological replicates.
Methods and source locations

Compound reported in the paper: Eribulin mesylate; Compound label in the paper: E7389 / eribulin

Applies to the material and assay reported in this paper; no salt conversion, stereoisomer substitution or validation of a current Adooq lot.

Materials and Methods: Dynamic Instability of Microtubule Minus Ends; Results: Eribulin Does Not Affect Dynamic Instability at Microtubule Minus Ends; Table 1 and footnotes a–e

Minus-end growth rate, control versus 100 nM eribulin: Table 1; 45–50 growth/shortening events per condition reported in methods; significance criterion 99% confidence by Student's t test — Materials and Methods: Dynamic Instability of Microtubule Minus Ends; Results: Eribulin Does Not Affect Dynamic Instability at Microtubule Minus Ends; Table 1 and footnotes a–e

Minus-end growing length, control versus 100 nM eribulin: Table 1 event analysis; ns means not significant under the paper's criterion — Materials and Methods: Dynamic Instability of Microtubule Minus Ends; Results: Eribulin Does Not Affect Dynamic Instability at Microtubule Minus Ends; Table 1 and footnotes a–e

MDR1 mRNA and P-glycoprotein expression in LS174T cells

Cell-based study · Human intestinal epithelial LS174T cells [2]

Eribulin increased MDR1 mRNA and P-glycoprotein protein expression relative to vehicle. Paclitaxel and cabazitaxel served as comparator drugs; their responses were not identical to eribulin.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MDR1 mRNA relative to ethanol controlRelative mRNA Increased; p < 0.01; mean ± SD of 3 independent experiments[2]
P-glycoprotein protein relative to β-actin and controlRelative protein Increased; p < 0.01; mean ± SD of 3 independent experiments[2]

Literature-Reported Treatment Conditions

Treatment concentration
2 μM eribulin mesylate
Exposure duration
48 h
Method
RT-qPCR normalized to ACTB and Western blot normalized to β-actin
Vehicle
Ethanol vehicle control
Reported limits
Final ethanol concentration not specified in the relevant main text. Exact fold changes are not tabulated and are not digitized from bars.
Methods and source locations

Compound reported in the paper: Eribulin mesylate; Compound label in the paper: E7389 / eribulin

Applies to the material and assay reported in this paper; no salt conversion, stereoisomer substitution or validation of a current Adooq lot.

Materials and methods 2.1, 2.2, 2.4 and 2.6; Results 3.1, paragraph introducing Figure 2; Figure 2A–C and caption

MDR1 mRNA relative to ethanol control: RT-qPCR, ACTB normalization and 2^−ΔΔCT analysis; one-way ANOVA followed by Dunnett's test — Materials and methods 2.1, 2.2, 2.4 and 2.6; Results 3.1, paragraph introducing Figure 2; Figure 2A–C and caption

P-glycoprotein protein relative to β-actin and control: C219 immunoblot and β-actin-normalized densitometry; Figure 2B representative blot, 2C quantification — Materials and methods 2.1, 2.2, 2.4 and 2.6; Results 3.1, paragraph introducing Figure 2; Figure 2A–C and caption

Fluorescent substrate accumulation after eribulin exposure

Cell-based study · Human intestinal epithelial LS174T cells [2]

After eribulin exposure and washout, cellular accumulation of rhodamine 123 and calcein-AM-derived fluorescence was reduced relative to vehicle. This is consistent with altered drug-efflux capacity but does not establish P-glycoprotein as the exclusive cause.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cellular uptake of rhodamine 123 and calcein-AM-derived calcein after drug washoutPercentage of ethanol control Both decreased; p < 0.01 versus control; mean ± SD of 6–9 measurements from 3 independent experiments[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 μM eribulin mesylate; subsequent probes: 20 μM rhodamine 123 or 1 μM calcein-AM
Exposure duration
96 h drug exposure, then washing and 1 h probe incubation at 37 °C
Method
Cell-associated fluorescence normalized to protein concentration and expressed relative to vehicle
Vehicle
Ethanol vehicle control
Reported limits
Final ethanol concentration not specified in the relevant main text. No transporter-inhibitor rescue is included in this experiment. Exact uptake percentages are not tabulated.
Methods and source locations

Compound reported in the paper: Eribulin mesylate; Compound label in the paper: E7389 / eribulin

Applies to the material and assay reported in this paper; no salt conversion, stereoisomer substitution or validation of a current Adooq lot.

Materials and methods 2.1, 2.2, 2.5 and 2.6; Results 3.2; Figure 3 and caption

Cellular uptake of rhodamine 123 and calcein-AM-derived calcein after drug washout: Fluorescence normalized to protein measured by BCA; separate probe incubations; one-way ANOVA followed by Dunnett's test — Materials and methods 2.1, 2.2, 2.5 and 2.6; Results 3.2; Figure 3 and caption

Eribulin Mesylate In Vivo Studies

In breast cancer xenografts, a single intravenous eribulin administration increased the Hoechst-based tumor-perfusion endpoint, with different dose responses in MX-1 and MDA-MB-231 models. Capecitabine reduced tumor growth without increasing that endpoint. These results support a vascular effect beyond tumor shrinkage in these models, without directly establishing improved delivery of another drug. [3]

Vascular and antitumor responses varied across a separate ten-model xenograft survey. Eribulin increased microvessel density significantly in six models, with a model-level association between vascular and antitumor responses (R² = 0.54). H460 showed no antitumor effect, limiting generalization across tumor models. [4]

Tumor perfusion after a single eribulin administration

Animal study · Female nude mice bearing human MX-1 or MDA-MB-231 breast cancer xenografts [3]

Hoechst-positive tumor area increased after eribulin in a model- and dose-dependent manner. Capecitabine inhibited MDA-MB-231 tumor growth without increasing the perfusion endpoint, arguing against tumor shrinkage alone explaining the finding.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor Hoechst 33342-positive area on day 6Perfused area relative to control Significantly increased at 1.0 and 3.0 mg/kg in MX-1, and at 0.1, 0.3, 1.0 and 3.0 mg/kg in MDA-MB-231; n = 10 mice/group; mean ± SEM[3]
MDA-MB-231 tumor growth and perfused area under comparator treatmentComparator response Capecitabine inhibited tumor growth (p < 0.05 in Figure 2e) but did not increase perfusion (Figure 2f); n = 5–6 mice/group; mean ± SEM[3]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
MX-1 eribulin dose response
0.1, 0.3, 1.0 or 3.0 mg/kg
Vehicle-treated tumor-bearing micePerfusion increased significantly at 1.0 and 3.0 mg/kg; no significant increase marked at 0.1 or 0.3 mg/kg.[3]
MDA-MB-231 eribulin dose response
0.1, 0.3, 1.0 or 3.0 mg/kg
Vehicle-treated tumor-bearing micePerfusion increased significantly at all four tested doses.[3]
MDA-MB-231 capecitabine comparator
540 mg/kg
Vehicle-treated tumor-bearing miceTumor growth inhibited, but Hoechst-positive area did not increase.[3]
MX-1 eribulin dose response
Model: Female nude mice, MX-1 xenograft
Route: Intravenous
Frequency: Single administration on day 1
Treatment course: Perfusion assessed day 6
Reported limits: Vehicle formulation not specified in selected main text.
MDA-MB-231 eribulin dose response
Model: Female nude mice, MDA-MB-231 xenograft
Route: Intravenous
Frequency: Single administration on day 1
Treatment course: Perfusion assessed day 6
Reported limits: Vehicle formulation not specified in selected main text.
MDA-MB-231 capecitabine comparator
Model: Female nude mice, MDA-MB-231 xenograft
Route: Oral
Frequency: Daily
Reported limits: Precise daily course and vehicle formulation not specified in selected main-text perfusion description.
Methods and source locations

Compound reported in the paper: Eribulin mesylate; Compound label in the paper: E7389 / eribulin

Applies to the material and assay reported in this paper; no salt conversion, stereoisomer substitution or validation of a current Adooq lot.

Materials and Methods: Compounds, cell lines and animals; Human breast cancer s.c. xenograft models; Hoechst 33342 perfusion assay; Statistical analyses; Results: Effects of eribulin on tumor perfusion; Figure 2a–f and caption

Tumor Hoechst 33342-positive area on day 6: Figure 2c–d; paper uses Dunnett multiple comparison test unless otherwise noted; Figure 2 marks p < 0.05, p < 0.01 or p < 0.001 versus vehicle — Materials and Methods: Compounds, cell lines and animals; Human breast cancer s.c. xenograft models; Hoechst 33342 perfusion assay; Statistical analyses; Results: Effects of eribulin on tumor perfusion; Figure 2a–f and caption

MDA-MB-231 tumor growth and perfused area under comparator treatment: Tumor volume-derived weight on day 8 and Hoechst-positive area; comparator monotherapy, not a combination — Materials and Methods: Compounds, cell lines and animals; Human breast cancer s.c. xenograft models; Hoechst 33342 perfusion assay; Statistical analyses; Results: Effects of eribulin on tumor perfusion; Figure 2a–f and caption

MX-1 eribulin dose response · Materials and Methods: Compounds, cell lines and animals; Human breast cancer s.c. xenograft models; Hoechst 33342 perfusion assay; Statistical analyses; Results: Effects of eribulin on tumor perfusion; Figure 2a–f and caption

MDA-MB-231 eribulin dose response · Materials and Methods: Compounds, cell lines and animals; Human breast cancer s.c. xenograft models; Hoechst 33342 perfusion assay; Statistical analyses; Results: Effects of eribulin on tumor perfusion; Figure 2a–f and caption

MDA-MB-231 capecitabine comparator · Materials and Methods: Compounds, cell lines and animals; Human breast cancer s.c. xenograft models; Hoechst 33342 perfusion assay; Statistical analyses; Results: Effects of eribulin on tumor perfusion; Figure 2a–f and caption

Tumor response and vascular density across ten xenograft models

Animal study · Female CAnN.Cg-Foxn1nu/CrlCrlj nude mice with H460, A549, H441, H1993, HCT116, Calu-6, HCC827, H1975, A427 or LOX xenografts [4]

A cross-model survey found significant microvessel-density increases in six of ten models and an association with antitumor effects. H460 showed no antitumor effect. The correlation does not establish a universal vascular mechanism or causation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Significant microvessel-density enhancement across ten xenograft modelsModel response count 6 of 10 models; n = 3 for MVD; day 7; mean ± SD; p < 0.05[4]
Association of MVD enhancement with antitumor effectsR² 0.54 across the ten-model survey[4]
Antitumor effect in H460 xenograftsTumor response No antitumor effect in H460; n = 6/group for tumor response; mean ± SD[4]

Conditions shared by the study groups

Route
Tail-vein injection
Frequency
One injection on day 0
Treatment course
MVD on day 7; model-specific longitudinal tumor follow-up
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Eribulin ten-model survey
1.5 mg/kg
Vehicle-treated tumor-bearing miceSignificant MVD increases in 6/10 models; cross-model R² = 0.54; H460 lacked antitumor response.[4]
Eribulin ten-model survey
Model: Female CAnN.Cg-Foxn1nu/CrlCrlj nude mice with H460, A549, H441, H1993, HCT116, Calu-6, HCC827, H1975, A427 or LOX xenografts
Reported limits: Vehicle formulation not specified in selected main text. n = 6/group for tumor response and n = 3 for MVD, not one common n.
Methods and source locations

Compound reported in the paper: Eribulin mesylate; Compound label in the paper: E7389 / eribulin

Applies to the material and assay reported in this paper; no salt conversion, stereoisomer substitution or validation of a current Adooq lot.

Materials and Methods: Drugs; Human cancer xenograft models; CD31/alpha-SMA immunohistochemistry; Statistical analysis; Results: Significance of vascular remodeling effects; Figure 1a–d and caption

Significant microvessel-density enhancement across ten xenograft models: CD31 immunohistochemistry; Figure 1b/caption and first Results subsection — Materials and Methods: Drugs; Human cancer xenograft models; CD31/alpha-SMA immunohistochemistry; Statistical analysis; Results: Significance of vascular remodeling effects; Figure 1a–d and caption

Association of MVD enhancement with antitumor effects: Figure 1d; MVD ratio versus ΔT/C; association across models, not a causal intervention — Materials and Methods: Drugs; Human cancer xenograft models; CD31/alpha-SMA immunohistochemistry; Statistical analysis; Results: Significance of vascular remodeling effects; Figure 1a–d and caption

Antitumor effect in H460 xenografts: Figure 1a and first Results paragraph; relative tumor volume time courses — Materials and Methods: Drugs; Human cancer xenograft models; CD31/alpha-SMA immunohistochemistry; Statistical analysis; Results: Significance of vascular remodeling effects; Figure 1a–d and caption

Eribulin ten-model survey · Materials and Methods: Drugs; Human cancer xenograft models; CD31/alpha-SMA immunohistochemistry; Statistical analysis; Results: Significance of vascular remodeling effects; Figure 1a–d and caption

Specifications

Manufacturer Adooq Bioscience
CAS Number 441045-17-6
Formula C41H63NO14S
Molecular Weight 826
Synonyms halichrondrin B analog; B1939; E7389; ER-086526; Halaven
SMILES
C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O.CS(=O)(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Eribulin Mesylate Research References

  1. [1] Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability Biochemistry (2010). PMID: 20030375 DOI: 10.1021/bi901810u Source material
  2. [2] Nabekura T, Kawasaki T, Jimura M, et al. Microtubule-targeting anticancer drug eribulin induces drug efflux transporter P-glycoprotein Biochemistry and biophysics reports (2020). PMID: 31993509 DOI: 10.1016/j.bbrep.2020.100727 Source material
  3. [3] Funahashi Y, Okamoto K, Adachi Y, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models Cancer science (2014). PMID: 25060424 DOI: 10.1111/cas.12488 Source material
  4. [4] Ito K, Hamamichi S, Abe T, et al. Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models Cancer science (2017). PMID: 28869796 DOI: 10.1111/cas.13392 Source material

Publications

3 publications citing this product

  1. Seungyeon Ryu, .et al. , Breast Cancer Res, 2025, Jun 23;27(1):113 PMID: 40551232
  2. Tomohiro Nabekura, .et al. , Biochem Biophys Rep, 2020, Mar; 21: 100727 PMID: 31993509
  3. Snyder C, .et al. , Toxicol In Vitro, 2018, Aug;50:109-123 PMID: 29427706

Added to your cart

View Cart Checkout
Loading...